Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Meropenem
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Marubeni Corporation
Deal Size : $301.0 million
Deal Type : Acquisition
Marubeni Acquires Sumitomo's Asia Pharma Unit in $480M Deal
Details : Through the acquisition, Marubeni will leverage the Sumitomo Asian approved products, which includes Meronem (meropenem trihydrate), indicated for Pneumonias.
Product Name : Meronem
Product Type : Antibiotic
Upfront Cash : Undisclosed
April 02, 2025
Lead Product(s) : Meropenem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Marubeni Corporation
Deal Size : $301.0 million
Deal Type : Acquisition
Lead Product(s) : MET-X,Meropenem
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Venus Remedies
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Venus Remedies Licenses MET-X from Infex for India Market
Details : The agreement authorizes Venus Remedies to spearhead the clinical development, registration, and commercialization of MET-X, an innovative metallo-beta-lactamase (MBL) inhibitor.
Product Name : MET-X
Product Type : Antibiotic
Upfront Cash : Undisclosed
February 27, 2025
Lead Product(s) : MET-X,Meropenem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Venus Remedies
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Meropenem
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 14, 2025
Lead Product(s) : Meropenem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Meropenem
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Biomedical Advanced Research and Development Authority
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 04, 2024
Lead Product(s) : Meropenem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Biomedical Advanced Research and Development Authority
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Meropenem
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
October 09, 2024
Lead Product(s) : Meropenem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Meropenem
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 28, 2023
Lead Product(s) : Meropenem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ANT3310,Meropenem
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MEM-ANT3310 combines the well-known carbapenem meropenem (MEM) with ANT3310, a breakthrough serine-beta-lactamase (SBL) inhibitor.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 25, 2023
Lead Product(s) : ANT3310,Meropenem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Xeruborbactam,Meropenem
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ORAvance (Xeruborbactam) an orally-administered combination product that delivers xeruborbactam to treat infections that occur in outpatient and community setting caused by drug-resistant gram-negative bacteria.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
October 17, 2022
Lead Product(s) : Xeruborbactam,Meropenem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KSP-1007,Meropenem
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Sumitomo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : It appears from nonclinical data that KSP-1007 broadly and strongly inhibits β-lactamases, which are enzymes that are produced by bacteria that can degrade carbapenem antibiotics. Sumitovant is leading the program of the compound in the U.S.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 02, 2022
Lead Product(s) : KSP-1007,Meropenem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Sumitomo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Fusidate,Ceftazidime,Meropenem
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Idera Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Idera Pharmaceuticals Acquires Aceragen
Details : The combined cash of the two companies is expected to provide runway into Q3 2023, funding the advancement of Aceragen’s pipeline, including ACG-701 (sodium fusidate) and ACG-801, through important 2023 clinical milestones.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
September 28, 2022
Lead Product(s) : Sodium Fusidate,Ceftazidime,Meropenem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Idera Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition